Evommune has raised a $50M Series B to develop new ways of treating inflammatory diseases.
Founded in 2020, the company has raised over $145M.
- Evommune aims to evolve immunology through its dynamic human tissue-based approach to discover, develop and deliver therapies that address symptoms and halt disease progression.
- Arix Bioscience EQT Life Sciences and SymBiosis led the funding round, with participation from Amplitude Ventures, Pivotal bioVenture Partners, and Andera Partners.
- The company aims to use the funds to support its three prioritized pipeline programs targeting highly prevalent inflammatory diseases, including EVO101, a novel small molecule inhibitor of IRAK4.
- The company is based in Palo Alto, California.
